Abstract: The present invention provides a method of enhancing an immune response to a vaccine by administering a vaccine and a population of isolated allogeneic human mesenchymal stem cells. The present invention also provides kits comprising a vaccine in a first container and a population of isolated allogeneic human mesenchymal stem cells in a second container.

Abstract: Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells. The methods of treatment involve the administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive function.

Abstract: Methods for the isolation of CD271+ stem cell populations are important in the prevention or treatment of cardio-vascular diseases and repair of cardiac tissue. The methods are applicable to stem cells from different sources and can be used to treat or prevent diseases or repair of tissues elsewhere in the organism's body.

Abstract: The present disclosure is directed to methods for determining responsiveness to cell therapy in a subject suffering from a cardiovascular disorder (e.g., cardiomyopathy) and methods of treating subjects suffering from a cardiovascular disorder.

Abstract: Molecular signatures that function as very sensitive diagnostic biomarker for myocarditis, heart disease and disorders thereof, are identified.

Abstract: Cardiac neural crest cells and methods for making and using the same to effect cardiac injury is described herein.

Abstract: Cardiac neural crest cells and methods for making and using the same to effect cardiac injury is described herein.

Abstract: The disclosure provides a method of obtaining a population of cardiomyogenic precursor cells. The method comprises (a) differentiating induced pluripotent stem cells (iPSCs) to iPSC-derived cardiac precursor cells; and (b) isolating cardiac precursor cells expressing mammalian growth hormone-releasing hormone receptor (GHRHR) to obtain a population of iPSC-derived cardiomyogenic precursor cells.

Abstract: Compositions and methods for treating sexual dysfunction and enhancing sexual satisfaction using isolated populations of mesenchymal stem cells are disclosed.

Abstract: A novel transcriptomic biomarker for prognosis in heart failure has a direct clinical application in prediction of prognosis in new onset heart failure, heart disease, heart disorders and associated heart conditions. This approach should improve individualization of cardiac care and help identify patients at highest risk for circulatory collapse within the first years of presentation with heart failure.

Abstract: Disclosed herein are compositions of GHRH agonists and peptides, and methods to treat disorders, such as ischemia and reperfusion injury. In one embodiment, a method of treating a reperfusion injury in a subject in need may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In additional embodiment, a method of promoting vasculogenesis in a mammal may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In a further embodiment, a method of promoting differentiation of mesenchymal stem cells into endothelial cells may involve contacting mesenchymal stem cells with at least one GHRH agonist peptide.

Abstract: The present invention provides a method of treating subjects with non-ischemic dilated cardiomyopathy by administering a therapeutically effective amount of an isolated population of allogeneic human mesenchymal stem cells. The present invention also provides a method of treating subjects with symptoms of aging frailty by administering a therapeutically effective amount of an isolated population of allogeneic human mesenchymal stem cells.

Abstract: The present invention provides a method of enhancing an immune response to a vaccine by administering a vaccine and a population of isolated allogeneic human mesenchymal stem cells. The present invention also provides kits comprising a vaccine in a first container and a population of isolated allogeneic human mesenchymal stem cells in a second container.

Abstract: A novel transcriptomic biomarker for prognosis in heart failure has a direct clinical application in prediction of prognosis in new onset heart failure, heart disease, heart disorders and associated heart conditions. This approach should improve individualization of cardiac care and help identify patients at highest risk for circulatory collapse within the first years of presentation with heart failure.

Abstract: Disclosed herein are compositions of GHRH agonists and peptides, and methods to treat disorders, such as ischemia and reperfusion injury. In one embodiment, a method of treating a reperfusion injury in a subject in need may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In additional embodiment, a method of promoting vasculogenesis in a mammal may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In a further embodiment, a method of promoting differentiation of mesenchymal stem cells into endothelial cells may involve contacting mesenchymal stem cells with at least one GHRH agonist peptide.

Abstract: Methods for the isolation of CD271+ stem cell populations are important in the prevention or treatment of cardiovascular diseases and repair of cardiac tissue. The methods are applicable to stem cells from different sources and can be used to treat or prevent diseases or repair of tissues elsewhere in the organism's body.

Abstract: Molecular signatures that function as very sensitive diagnostic biomarker for myocarditis, heart disease and disorders thereof, are identified.

Abstract: Disclosed herein are compositions of GHRH agonists and peptides, and methods to treat disorders, such as ischemia and reperfusion injury. In one embodiment, a method of treating a reperfusion injury in a subject in need may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In additional embodiment, a method of promoting vasculogenesis in a mammal may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In a further embodiment, a method of promoting differentiation of mesenchymal stem cells into endothelial cells may involve contacting mesenchymal stem cells with at least one GHRH agonist peptide.

Abstract: The present disclosure is directed to materials and methods for treating endothelial dysfunction in a subject in need thereof. Methods of determining efficacy of treatment are also provided.

Abstract: Cardiac neural crest cells and methods for making and using the same to effect cardiac injury is described herein.